Journal of

Case Reports and Images in Oncology

 
  Table of Contents    
Case Report
 
Syringoid eccrine carcinoma: A case report and literature review of therapeutic options
Munaf AL-Kadhimi1, Tamarah AL-Dawoodi1, Julio Peguero1, Luis T. Campos1
1Oncology Consultants, Research Department, 2130 West Holcombe Blvd. 10th Floor, Houston, Texas.

Article ID: 100023Z10MA2016
doi:10.5348/Z10-2016-23-CR-14

Address correspondence to:
Dr. Julio Peguero
MD, 2130 West Holcombe Blvd. 10th Floor
Houston
Texas 77030

Access full text article on other devices

  Access PDF of article on other devices

[HTML Full Text]   [PDF Full Text] [Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar]

How to cite this article:
AL-Kadhimi M, AL-Dawoodi T, Peguero J, Campos LT. Syringoid eccrine carcinoma: A case report and literature review of therapeutic options. J Case Rep Images Oncology 2016;2:57–60.


Abstract
Introduction: Syringoid eccrine carcinoma is exceedingly infiltrative neoplasm, focally destructive, slowly growing adnexal tumor, derived from eccrine sweat glands. It is frequently misdiagnosed, both clinically and histologically, with other benign and malignant neoplasms. Owing to perineural invasion and destruction, the tumor recurrence is high. However, the regional or distant metastases are very rare. The local aggressive nature of the tumor and the high recurrence rate may necessitate further sophisticated procedures.
Case Report: We report a case of a 65-year-old Siberian female who has initially missed diagnosed with benign lesions and subsequently found to have syringocarcinoma. The patient had multiple recurrences treated with surgical resection, cisplatin and docetaxel, radiation therapy and laser therapy. Computed tomography scan obtained and revealed metastatic disease involving the bone. Due to the rarity of this type of skin cancer, next generation sequencing was obtained. Based on literature review, we decided to treat the patient with capecitabine. After three cycles of capecitabine, the patient had clinical and radiological response.
Conclusion: Owing to the scarcity of this tumor presentation, more therapeutic options remain to be defined. Oral 5FU seems a reasonable option in this setting. Although the tumor mutation burden is low in this patient, immunotherapy may be a reasonable therapeutic niche.

Keywords: Capecitabine, Multiple recurrence, Next generation sequencing, Skin appendageal carcinoma, Syringoid eccrine carcinoma


[HTML Full Text]   [PDF Full Text]

Author Contributions
Munaf AL-Kadhimi – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Tamarah AL-Dawoodi – Substantial contribution to conception and design, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Julio Peguero – Substantial contribution to conception and design, Analysis and interpretation of data, Final approval of the version to be published
Luis T. Campos – Substantial contribution to conception and design, Analysis and interpretation of data, Final approval of the version to be published
Guarantor of submission
The corresponding author is the guarantor of submission.
Source of support
None
Conflict of interest
Dr. Peguero serves in the speaker bureau for Foundation Medicine, Bristol Myers Squibb and Bayer. He directs phase 1 and 2 clinical trials that are funded by the Pharmaceutical Industry at the Oncology Consultants Research Department.
Copyright
© 2016 Munaf AL-Kadhimi et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.



  Home line About the Journal line Aim and Scope line Open Access line Archives
Apply as Editor line Apply as Reviewer line Submit Reviews - Editors line Submit Reviews - Reviewers
Instructions for Authors line Templates to Use line Copyright Form line Author Checklist
Online Submission line Email Submission line Submit Revision line Submit All Forms line Submit Page Proofs
Terms of Service line Privacy policy line Disclaimer line FAQ line Contact: Journal line Contact: Edorium Journals line Site Map
 
  Copyright © 2017. Edorium. All rights reserved.